{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:31:14Z","timestamp":1792297874157,"version":"4.4.0"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40261-024-01377-9","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T01:01:38Z","timestamp":1718931698000},"page":"471-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Current Findings and Potential Mechanisms of KarXT (Xanomeline\u2013Trospium) in Schizophrenia Treatment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-9419","authenticated-orcid":false,"given":"Ali","family":"Azargoonjahromi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"2","key":"1377_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Marques TR, Howes OD. Schizophrenia\u2014an overview. JAMA Psychiat. 2020;77(2):201\u201310.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"1377_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/BF01563716","volume":"35","author":"HF Searles","year":"1961","unstructured":"Searles HF. Schizophrenia and the inevitability of death. Psychiatr Q. 1961;35(4):631\u201365.","journal-title":"Psychiatr Q"},{"issue":"8 Suppl","key":"1377_CR3","first-page":"S160","volume":"20","author":"DC Javitt","year":"2014","unstructured":"Javitt DC. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview. Am J Manag Care. 2014;20(8 Suppl):S160\u20135.","journal-title":"Am J Manag Care"},{"issue":"10159","key":"1377_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858.","journal-title":"Lancet"},{"key":"1377_CR5","unstructured":"Sokan A. Daily use of the medication adherence mobile phone application, Medisafe, to improve adherence over a 10-week period among African American adults, ages 25-60 years, diagnosed with schizophrenia. University of Massachusetts Global; 2023. No: 30425489."},{"issue":"1","key":"1377_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-023-04555-9","volume":"23","author":"A Shanko","year":"2023","unstructured":"Shanko A, Abute L, Tamirat T. Attitudes towards schizophrenia and associated factors among community members in Hossana town: a mixed method study. BMC Psychiatry. 2023;23(1):1\u201310.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1377_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2022-100823","volume":"35","author":"X Li","year":"2022","unstructured":"Li X, Zhou W, Yi Z. A glimpse of gender differences in schizophrenia. Gen Psychiatry. 2022;35(4): e100823. https:\/\/doi.org\/10.1136\/gpsych-2022-100823.","journal-title":"Gen Psychiatry"},{"issue":"1","key":"1377_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pneurobio.2010.09.003","volume":"93","author":"AS Brown","year":"2011","unstructured":"Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93(1):23\u201358. https:\/\/doi.org\/10.1016\/j.pneurobio.2010.09.003.","journal-title":"Prog Neurobiol"},{"key":"1377_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/genes12121850","author":"MH Wahbeh","year":"2021","unstructured":"Wahbeh MH, Avramopoulos D. Gene-environment interactions in schizophrenia: a literature review. Genes (Basel). 2021. https:\/\/doi.org\/10.3390\/genes12121850.","journal-title":"Genes (Basel)"},{"key":"1377_CR10","first-page":"99","volume-title":"Advances in genetics","author":"J van de Leemput","year":"2016","unstructured":"van de Leemput J, Hess JL, Glatt SJ, Tsuang MT. Chapter Three\u2014Genetics of schizophrenia: historical insights and prevailing evidence. In: Friedmann T, Dunlap JC, Goodwin SF, editors. Advances in genetics. London: Academic Press; 2016. p. 99\u2013141."},{"issue":"1","key":"1377_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.psc.2009.12.003","volume":"33","author":"PV Gejman","year":"2010","unstructured":"Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am. 2010;33(1):35\u201366. https:\/\/doi.org\/10.1016\/j.psc.2009.12.003.","journal-title":"Psychiatr Clin North Am"},{"issue":"10039","key":"1377_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/s0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(15)01121-6.","journal-title":"Lancet"},{"issue":"4","key":"1377_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ajp.2013.03.012","volume":"6","author":"P Parakh","year":"2013","unstructured":"Parakh P, Basu D. Cannabis and psychosis: have we found the missing links? Asian J Psychiatry. 2013;6(4):281\u20137. https:\/\/doi.org\/10.1016\/j.ajp.2013.03.012.","journal-title":"Asian J Psychiatry"},{"issue":"2","key":"1377_CR14","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/S2542-5196(20)30004-8","volume":"4","author":"S Antonsen","year":"2020","unstructured":"Antonsen S, Mok PL, Webb RT, et al. Exposure to air pollution during childhood and risk of developing schizophrenia: a national cohort study. Lancet Planetary Health. 2020;4(2):e64\u201373.","journal-title":"Lancet Planetary Health"},{"issue":"28","key":"1377_CR15","doi-asserted-by":"publisher","first-page":"8295","DOI":"10.12998\/wjcc.v9.i28.8295","volume":"9","author":"OJ Onaolapo","year":"2021","unstructured":"Onaolapo OJ, Onaolapo AY. Nutrition, nutritional deficiencies, and schizophrenia: an association worthy of constant reassessment. World J Clin Cases. 2021;9(28):8295\u2013311. https:\/\/doi.org\/10.12998\/wjcc.v9.i28.8295.","journal-title":"World J Clin Cases"},{"issue":"5","key":"1377_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/inm.12865","volume":"30","author":"Q Wang","year":"2021","unstructured":"Wang Q, Zhu X, Jiang X, et al. Relationship between stressful life events, coping styles, and schizophrenia relapse. Int J Ment Health Nurs. 2021;30(5):1149\u201359. https:\/\/doi.org\/10.1111\/inm.12865.","journal-title":"Int J Ment Health Nurs"},{"issue":"1","key":"1377_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41537-023-00389-2","volume":"9","author":"Q Xu","year":"2023","unstructured":"Xu Q, Cai M, Ji Y, et al. Identifying the mediating role of socioeconomic status on the relationship between schizophrenia and major depressive disorder: a Mendelian randomisation analysis. Schizophrenia. 2023;9(1):53. https:\/\/doi.org\/10.1038\/s41537-023-00389-2.","journal-title":"Schizophrenia"},{"key":"1377_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.980614","author":"T Samuel","year":"2022","unstructured":"Samuel T, Nigussie K, Mirkena Y, Azale T. Relationship between social support and schizophrenia relapse among patients with schizophrenia on follow-up at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: a case-control study. Original Research. Front Psychiatry. 2022. https:\/\/doi.org\/10.3389\/fpsyt.2022.980614.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1377_CR19","first-page":"395","volume":"33","author":"RJ Van Lieshout","year":"2008","unstructured":"Van Lieshout RJ, Voruganti LP. Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms. J Psychiatry Neurosci. 2008;33(5):395\u2013404.","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"1377_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1176\/appi.ajp.160.3.464","volume":"160","author":"HJ S\u00f8rensen","year":"2003","unstructured":"S\u00f8rensen HJ, Mortensen EL, Reinisch JM, Mednick SA. Do hypertension and diuretic treatment in pregnancy increase the risk of schizophrenia in offspring? Am J Psychiatry. 2003;160(3):464\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.160.3.464.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1377_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1192\/bjp.165.3.357","volume":"165","author":"L Rifkin","year":"1994","unstructured":"Rifkin L, Lewis S, Jones P, Toone B, Murray R. Low birth weight and schizophrenia. Br J Psychiatry. 1994;165(3):357\u201362. https:\/\/doi.org\/10.1192\/bjp.165.3.357.","journal-title":"Br J Psychiatry"},{"key":"1377_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23082087","author":"P St\u0119pnicki","year":"2018","unstructured":"St\u0119pnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018. https:\/\/doi.org\/10.3390\/molecules23082087.","journal-title":"Molecules"},{"key":"1377_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519\u201334.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1377_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/B978-0-12-813693-5.00013-7","volume-title":"Neurobiology of abnormal emotion and motivated behaviors","author":"D Foti","year":"2018","unstructured":"Foti D, Novak KD, Hill KE, Ait OB. 13 - Neurophysiological assessment of anhedonia in depression and schizophrenia. In: Sangha S, Foti D, editors. Neurobiology of abnormal emotion and motivated behaviors. London: Academic Press; 2018. p. 242\u201356."},{"issue":"1","key":"1377_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0447.1990.tb01350.x","volume":"82","author":"K Mueser","year":"1990","unstructured":"Mueser K, Bellack A, Brady E. Hallucinations in schizophrenia. Acta Psychiatr Scand. 1990;82(1):26\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"1377_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/135468096396451","volume":"1","author":"AMP Bentham","year":"1996","unstructured":"Bentham AMP, McKay A, Quemada I, Clare L, Eastwood N, McKenna P. Delusions in schizophrenia: a phenomenological and psychological exploration. Cogn Neuropsychiatry. 1996;1(4):289\u2013304.","journal-title":"Cogn Neuropsychiatry"},{"key":"1377_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/ndt.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519\u201334. https:\/\/doi.org\/10.2147\/ndt.S225643.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1377_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/wps.20385","volume":"16","author":"SR Marder","year":"2017","unstructured":"Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14\u201324.","journal-title":"World Psychiatry"},{"issue":"3","key":"1377_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjc.12248","volume":"59","author":"I Butcher","year":"2020","unstructured":"Butcher I, Berry K, Haddock G. Understanding individuals\u2019 subjective experiences of negative symptoms of schizophrenia: a qualitative study. Br J Clin Psychol. 2020;59(3):319\u201334.","journal-title":"Br J Clin Psychol"},{"issue":"8","key":"1377_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","volume":"5","author":"S Galderisi","year":"2018","unstructured":"Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664\u201377.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1377_CR31","first-page":"25","volume":"26","author":"T Sharma","year":"2003","unstructured":"Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin. 2003;26(1):25\u201340.","journal-title":"Psychiatr Clin"},{"issue":"1","key":"1377_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","volume":"14","author":"B Elvevag","year":"2000","unstructured":"Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1\u201321.","journal-title":"Crit Rev Neurobiol"},{"key":"1377_CR33","first-page":"91","volume-title":"Clinical handbook of schizophrenia","author":"GN Savla","year":"2008","unstructured":"Savla GN, Moore DJ, Palmer BW. Cognitive functioning in schizophrenia. In: Clinical handbook of schizophrenia. New York: The Guilford Press; 2008. p. 91\u20139."},{"key":"1377_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-012-0001-4","volume":"29","author":"H Kitchen","year":"2012","unstructured":"Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012;29:148\u201362.","journal-title":"Adv Ther"},{"issue":"4","key":"1377_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4103\/psychiatry.IndianJPsychiatry_464_17","volume":"59","author":"M George","year":"2017","unstructured":"George M, Maheshwari S, Chandran S, Manohar JS, Sathyanarayana Rao TS. Understanding the schizophrenia prodrome. Indian J Psychiatry. 2017;59(4):505\u20139. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_464_17.","journal-title":"Indian J Psychiatry"},{"issue":"4","key":"1377_CR36","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/schbul\/sbl051","volume":"33","author":"M Morrens","year":"2007","unstructured":"Morrens M, Hulstijn W, Sabbe B. Psychomotor slowing in schizophrenia. Schizophr Bull. 2007;33(4):1038\u201353. https:\/\/doi.org\/10.1093\/schbul\/sbl051.","journal-title":"Schizophr Bull"},{"key":"1377_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.schres.2017.10.007","volume":"200","author":"D Hirjak","year":"2018","unstructured":"Hirjak D, Kubera KM, Thomann PA, Wolf RC. Motor dysfunction as an intermediate phenotype across schizophrenia and other psychotic disorders: progress and perspectives. Schizophr Res. 2018;200:26\u201334. https:\/\/doi.org\/10.1016\/j.schres.2017.10.007.","journal-title":"Schizophr Res"},{"issue":"1","key":"1377_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161(1):160\u20133. https:\/\/doi.org\/10.1176\/appi.ajp.161.1.160.","journal-title":"Am J Psychiatry"},{"key":"1377_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014: 656370. https:\/\/doi.org\/10.1155\/2014\/656370.","journal-title":"Biomed Res Int"},{"issue":"1","key":"1377_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1530\/alphapsychiatry.2021.21371","volume":"23","author":"S Uzman \u00d6zbek","year":"2022","unstructured":"Uzman \u00d6zbek S, Alptekin K. Thought disorder as a neglected dimension in schizophrenia. Alpha Psychiatry. 2022;23(1):5\u201311. https:\/\/doi.org\/10.1530\/alphapsychiatry.2021.21371.","journal-title":"Alpha Psychiatry"},{"key":"1377_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02563-z","author":"RJ Sharkey","year":"2024","unstructured":"Sharkey RJ, Bacon C, Peterson Z, et al. Differences in the neural correlates of schizophrenia with positive and negative formal thought disorder in patients with schizophrenia in the ENIGMA dataset. Mol Psychiatry. 2024. https:\/\/doi.org\/10.1038\/s41380-024-02563-z.","journal-title":"Mol Psychiatry"},{"key":"1377_CR42","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3179362\/v1","author":"T Nickl-Jockschat","year":"2023","unstructured":"Nickl-Jockschat T, Sharkey R, Bacon C, et al. Neural correlates of positive and negative formal thought disorder in individuals with schizophrenia: an ENIGMA schizophrenia working group study. Res Sq. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3179362\/v1.","journal-title":"Res Sq"},{"key":"1377_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.640921","author":"J Nordgaard","year":"2021","unstructured":"Nordgaard J, Gravesen-Jensen M, Buch-Pedersen M, Parnas J. Formal thought disorder and self-disorder: an empirical study. Front Psychiatry. 2021. https:\/\/doi.org\/10.3389\/fpsyt.2021.640921.","journal-title":"Front Psychiatry"},{"issue":"02","key":"1377_CR44","first-page":"77","volume":"12","author":"FH Farah","year":"2018","unstructured":"Farah FH. Schizophrenia: an overview. Asian J Pharm. 2018;12(02):77.","journal-title":"Asian J Pharm"},{"key":"1377_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.789179","author":"GM Giordano","year":"2021","unstructured":"Giordano GM, Bucci P, Mucci A, Pezzella P, Galderisi S. Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review. Front Psychiatry. 2021. https:\/\/doi.org\/10.3389\/fpsyt.2021.789179.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1377_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/schbul\/17.1.27","volume":"17","author":"NC Andreasen","year":"1991","unstructured":"Andreasen NC, Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull. 1991;17(1):27\u201349.","journal-title":"Schizophr Bull"},{"key":"1377_CR47","volume":"1","author":"K Soares-Weiser","year":"2015","unstructured":"Soares-Weiser K, Maayan N, Bergman H, et al. First rank symptoms for schizophrenia. Cochrane Database Syst Rev. 2015;1: CD010653.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1377_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169\u201379.","journal-title":"Br Med Bull"},{"issue":"4","key":"1377_CR49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4088\/JCP.v68n0417","volume":"68","author":"AA Sepehry","year":"2007","unstructured":"Sepehry AA, Potvin S, \u00c9lie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68(4):604\u201310.","journal-title":"J Clin Psychiatry"},{"key":"1377_CR50","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/ndt.S62266","volume":"11","author":"YM Mao","year":"2015","unstructured":"Mao YM, Zhang MD. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat. 2015;11:701\u201313. https:\/\/doi.org\/10.2147\/ndt.S62266.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"1377_CR51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","volume":"173","author":"B Helfer","year":"2016","unstructured":"Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876\u201386. https:\/\/doi.org\/10.1176\/appi.ajp.2016.15081035.","journal-title":"Am J Psychiatry"},{"key":"1377_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajp.2014.08.002","volume":"11","author":"D Bruijnzeel","year":"2014","unstructured":"Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatry. 2014;11:3\u20137.","journal-title":"Asian J Psychiatry"},{"issue":"suppl 1","key":"1377_CR53","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4088\/JCP.10075su1.01","volume":"72","author":"R Tandon","year":"2011","unstructured":"Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72(suppl 1):1151.","journal-title":"J Clin Psychiatry"},{"key":"1377_CR54","volume-title":"StatPearls [Internet]","author":"MA Ameer","year":"2023","unstructured":"Ameer MA, Saadabadi A. Neuroleptic medications. In: StatPearls [Internet]. Florida: StatPearls Publishing; 2023."},{"key":"1377_CR55","volume-title":"StatPearls [Internet]","author":"K Chokhawala","year":"2023","unstructured":"Chokhawala K, Stevens L. Antipsychotic medications. In: StatPearls [Internet]. Florida: StatPearls Publishing; 2023."},{"issue":"4","key":"1377_CR56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14740338.2024.2328812","volume":"23","author":"K Ward","year":"2024","unstructured":"Ward K, Citrome L. Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia. Expert Opin Drug Saf. 2024;23(4):399\u2013409. https:\/\/doi.org\/10.1080\/14740338.2024.2328812.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"1377_CR57","doi-asserted-by":"publisher","first-page":"pyw066","DOI":"10.1093\/ijnp\/pyw066","volume":"19","author":"A Frazer","year":"2016","unstructured":"Frazer A, Blier P. A Neuroscience-Based Nomenclature (NbN) for psychotropic agents. Int J Neuropsychopharmacol. 2016;19(8):pyw066. https:\/\/doi.org\/10.1093\/ijnp\/pyw066.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"1377_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3928\/02793695-20230607-02","volume":"61","author":"E Hutson","year":"2023","unstructured":"Hutson E, Ellington E, Hardy L. Neuroscience-based nomenclature for psychotropic medication. J Psychosoc Nurs Ment Health Serv. 2023;61(7):9\u201313. https:\/\/doi.org\/10.3928\/02793695-20230607-02.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"12","key":"1377_CR59","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","volume":"25","author":"J Zohar","year":"2015","unstructured":"Zohar J, Stahl S, Moller HJ, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-Based Nomenclature. Eur Neuropsychopharmacol. 2015;25(12):2318\u201325. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.08.019.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"1377_CR60","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/npp.2017.33","volume":"42","author":"P Blier","year":"2017","unstructured":"Blier P, Oquendo MA, Kupfer DJ. Progress on the Neuroscience-Based Nomenclature (NbN) for psychotropic medications. Neuropsychopharmacology. 2017;42(10):1927\u20138. https:\/\/doi.org\/10.1038\/npp.2017.33.","journal-title":"Neuropsychopharmacology"},{"key":"1377_CR61","unstructured":"Wilson M, Tripp J. Clomipramine (2019)."},{"issue":"6","key":"1377_CR62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-7843.2005.pto_96696601.x","volume":"96","author":"SH Sindrup","year":"2005","unstructured":"Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96(6):399\u2013409. https:\/\/doi.org\/10.1111\/j.1742-7843.2005.pto_96696601.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"1377_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.31887\/DCNS.1999.1.1\/hgrunze","volume":"1","author":"H Grunze","year":"1999","unstructured":"Grunze H, Schl\u00f6sser S, Amann B, Walden J. Anticonvulsant drugs in bipolar disorder. Dialogues Clin Neurosci. 1999;1(1):24\u201340. https:\/\/doi.org\/10.31887\/DCNS.1999.1.1\/hgrunze.","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"1377_CR64","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/15622975.2016.1193626","volume":"17","author":"J Zohar","year":"2016","unstructured":"Zohar J, Kasper S. Neuroscience-based Nomenclature (NbN): a call for action. World J Biol Psychiatry. 2016;17(5):318\u201320. https:\/\/doi.org\/10.1080\/15622975.2016.1193626.","journal-title":"World J Biol Psychiatry"},{"issue":"36","key":"1377_CR65","first-page":"8","volume":"57","author":"J Zohar","year":"2022","unstructured":"Zohar J, Levy DM. Neuroscience-based nomenclature of psychotropics: progress report. Eur Neuropsychopharmacol. 2022;57(36):8.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"1377_CR66","first-page":"e488","volume":"64","author":"N Drummond","year":"2018","unstructured":"Drummond N, McCleary L, Freiheit E, et al. Antidepressant and antipsychotic prescribing in primary care for people with dementia. Can Fam Physician. 2018;64(11):e488\u201397.","journal-title":"Can Fam Physician"},{"key":"1377_CR67","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.2147\/cia.S178216","volume":"13","author":"AA Jennings","year":"2018","unstructured":"Jennings AA, Guerin N, Foley T. Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study. Clin Interv Aging. 2018;13:2107\u201317. https:\/\/doi.org\/10.2147\/cia.S178216.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"1377_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14656566.2018.1543409","volume":"20","author":"J Faden","year":"2019","unstructured":"Faden J, Citrome L. Resistance is not futile: treatment-refractory schizophrenia\u2014overview, evaluation and treatment. Expert Opin Pharmacother. 2019;20(1):11\u201324. https:\/\/doi.org\/10.1080\/14656566.2018.1543409.","journal-title":"Expert Opin Pharmacother"},{"issue":"29","key":"1377_CR69","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","volume":"16","author":"P Li","year":"2016","unstructured":"Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem. 2016;16(29):3385\u2013403. https:\/\/doi.org\/10.2174\/1568026616666160608084834.","journal-title":"Curr Top Med Chem"},{"key":"1377_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.815456","volume":"8","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Skrede S, Milbank E, Andriantsitohaina R, L\u00f3pez M, Fern\u00f8 J. Understanding the effects of antipsychotics on appetite control. Front Nutr. 2021;8: 815456. https:\/\/doi.org\/10.3389\/fnut.2021.815456.","journal-title":"Front Nutr"},{"key":"1377_CR71","unstructured":"Abou-Setta AM, Mousavi SS, Spooner C, et al. AHRQ comparative effectiveness reviews. First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Agency for Healthcare Research and Quality (US); 2012. Report No.: 12-EHC054-EF."},{"issue":"11","key":"1377_CR72","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2045125318781475","volume":"8","author":"PM Haddad","year":"2018","unstructured":"Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303\u201318. https:\/\/doi.org\/10.1177\/2045125318781475.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1377_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249532","author":"D Grinchii","year":"2020","unstructured":"Grinchii D, Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21249532.","journal-title":"Int J Mol Sci"},{"key":"1377_CR74","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/B978-0-7020-7167-6.00021-X","volume-title":"Medical pharmacology and therapeutics","author":"DG Waller","year":"2018","unstructured":"Waller DG, Sampson AP. 21 - Schizophrenia and bipolar disorder. In: Waller DG, Sampson AP, editors. Medical pharmacology and therapeutics. 5th ed. Amsterdam: Elsevier; 2018. p. 287\u201396.","edition":"5"},{"issue":"6","key":"1377_CR75","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0004867419837358","volume":"53","author":"AT Olagunju","year":"2019","unstructured":"Olagunju AT, Clark SR, Baune BT. Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome. Aust N Z J Psychiatry. 2019;53(6):509\u201327.","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"1377_CR76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","volume":"17","author":"TS Stroup","year":"2018","unstructured":"Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341\u201356. https:\/\/doi.org\/10.1002\/wps.20567.","journal-title":"World Psychiatry"},{"key":"1377_CR77","doi-asserted-by":"publisher","unstructured":"Blair DT, Dauner A. Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. Nurse Pract. 1992;17(11):56, 62\u20134, 67. https:\/\/doi.org\/10.1097\/00006205-199211000-00018.","DOI":"10.1097\/00006205-199211000-00018"},{"issue":"1","key":"1377_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","volume":"1","author":"BD Berman","year":"2011","unstructured":"Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41\u20137. https:\/\/doi.org\/10.1177\/1941875210386491.","journal-title":"Neurohospitalist"},{"key":"1377_CR79","volume-title":"StatPearls","author":"K Chokhawala","year":"2023","unstructured":"Chokhawala K, Stevens L. Antipsychotic medications. In: StatPearls. Florida: StatPearls Publishing; 2023."},{"issue":"3","key":"1377_CR80","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/a:1024122706337","volume":"74","author":"W Zareba","year":"2003","unstructured":"Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q Fall. 2003;74(3):291\u2013306. https:\/\/doi.org\/10.1023\/a:1024122706337.","journal-title":"Psychiatr Q Fall"},{"issue":"5","key":"1377_CR81","first-page":"617","volume":"81","author":"J Muench","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u201322.","journal-title":"Am Fam Physician"},{"key":"1377_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.08.016","volume":"131","author":"FC Nucifora Jr","year":"2019","unstructured":"Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131: 104257. https:\/\/doi.org\/10.1016\/j.nbd.2018.08.016.","journal-title":"Neurobiol Dis"},{"key":"1377_CR83","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/325052","volume":"2014","author":"M Quarantelli","year":"2014","unstructured":"Quarantelli M, Palladino O, Prinster A, et al. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia. BioMed Res Int. 2014;2014: 325052. https:\/\/doi.org\/10.1155\/2014\/325052.","journal-title":"BioMed Res Int"},{"issue":"3","key":"1377_CR84","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/schbul\/sby095","volume":"45","author":"MT Samara","year":"2019","unstructured":"Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? an analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45(3):639\u201346. https:\/\/doi.org\/10.1093\/schbul\/sby095.","journal-title":"Schizophr Bull"},{"issue":"4","key":"1377_CR85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000477313","volume":"86","author":"G Chouinard","year":"2017","unstructured":"Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86(4):189\u2013219. https:\/\/doi.org\/10.1159\/000477313.","journal-title":"Psychother Psychosom"},{"issue":"3","key":"1377_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115\u201320. https:\/\/doi.org\/10.1192\/bjp.2021.61.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1377_CR87","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"R Goldschlager","year":"2016","unstructured":"Goldschlager R, Kisely S, McCartney L, Siskind D. Clozapine v. First- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385\u201392. https:\/\/doi.org\/10.1192\/bjp.bp.115.177261.","journal-title":"Br J Psychiatry"},{"key":"1377_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006324.pub2","volume":"3","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;3: CD006324. https:\/\/doi.org\/10.1002\/14651858.CD006324.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1377_CR89","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","volume":"73","author":"MT Samara","year":"2016","unstructured":"Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiat. 2016;73(3):199\u2013210. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.2955.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1377_CR90","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1124\/jpet.121.000979","volume":"381","author":"SRJ Hoare","year":"2022","unstructured":"Hoare SRJ, Kudwa AE, Luo R, Grigoriadis DE. Efficacy of vesicular monoamine transporter 2 inhibition and synergy with antipsychotics in animal models of schizophrenia. J Pharmacol Exp Ther. 2022;381(2):79\u201395. https:\/\/doi.org\/10.1124\/jpet.121.000979.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1377_CR91","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-023-06488-3","volume":"241","author":"A Connolly","year":"2024","unstructured":"Connolly A, Wallman P, Dzahini O, Howes O, Taylor D. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis. Psychopharmacology. 2024;241(2):225\u201341. https:\/\/doi.org\/10.1007\/s00213-023-06488-3.","journal-title":"Psychopharmacology"},{"issue":"16","key":"1377_CR92","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1911772.","journal-title":"N Engl J Med"},{"key":"1377_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413185","author":"N Dedic","year":"2021","unstructured":"Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222413185.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1377_CR94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tins.2022.10.010","volume":"46","author":"EF Halff","year":"2023","unstructured":"Halff EF, Rutigliano G, Garcia-Hidalgo A, Howes OD. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023;46(1):60\u201374. https:\/\/doi.org\/10.1016\/j.tins.2022.10.010.","journal-title":"Trends Neurosci"},{"issue":"3","key":"1377_CR95","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/157015908785777247","volume":"6","author":"AV Terry Jr","year":"2008","unstructured":"Terry AV Jr. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol. 2008;6(3):286\u201392. https:\/\/doi.org\/10.2174\/157015908785777247.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"1377_CR96","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.neuropharm.2010.12.001","volume":"62","author":"M Sarter","year":"2012","unstructured":"Sarter M, Lustig C, Taylor SF. Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology. 2012;62(3):1544\u201353. https:\/\/doi.org\/10.1016\/j.neuropharm.2010.12.001.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1377_CR97","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/schbul\/sbi006","volume":"31","author":"M Sarter","year":"2005","unstructured":"Sarter M, Nelson CL, Bruno JP. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull. 2005;31(1):117\u201338. https:\/\/doi.org\/10.1093\/schbul\/sbi006.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1377_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007967.pub2","volume":"1","author":"J Singh","year":"2012","unstructured":"Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012;1(1): CD007967. https:\/\/doi.org\/10.1002\/14651858.CD007967.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1377_CR99","volume-title":"StatPearls","author":"C Sam","year":"2024","unstructured":"Sam C, Bordoni B. Physiology, acetylcholine. In: StatPearls. Florida: StatPearls Publishing; 2024."},{"issue":"1","key":"1377_CR100","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"MR Picciotto","year":"2012","unstructured":"Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76(1):116\u201329. https:\/\/doi.org\/10.1016\/j.neuron.2012.08.036.","journal-title":"Neuron"},{"issue":"12","key":"1377_CR101","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.18203\/2319-2003.ijbcp20195296","volume":"8","author":"LK Bairy","year":"2019","unstructured":"Bairy LK, Kumar S. Neurotransmitters and neuromodulators involved in learning and memory. Int J Basic Clin Pharmacol. 2019;8(12):2777\u201383.","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"2","key":"1377_CR102","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bbr.2010.11.033","volume":"221","author":"I Klinkenberg","year":"2011","unstructured":"Klinkenberg I, Sambeth A, Blokland A. Acetylcholine and attention. Behav Brain Res. 2011;221(2):430\u201342.","journal-title":"Behav Brain Res"},{"issue":"1","key":"1377_CR103","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/cn400189s","volume":"5","author":"P Seeman","year":"2014","unstructured":"Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci. 2014;5(1):24\u20139. https:\/\/doi.org\/10.1021\/cn400189s.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1377_CR104","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0006-3223(99)00029-3","volume":"46","author":"RR Conley","year":"1999","unstructured":"Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 1999;46(1):73\u20137. https:\/\/doi.org\/10.1016\/s0006-3223(99)00029-3.","journal-title":"Biol Psychiatry"},{"key":"1377_CR105","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.conb.2014.06.004","volume":"29","author":"MJ Higley","year":"2014","unstructured":"Higley MJ, Picciotto MR. Neuromodulation by acetylcholine: examples from schizophrenia and depression. Curr Opin Neurobiol. 2014;29:88\u201395. https:\/\/doi.org\/10.1016\/j.conb.2014.06.004.","journal-title":"Curr Opin Neurobiol"},{"issue":"79","key":"1377_CR106","first-page":"413","volume":"14","author":"DJ Foster","year":"2012","unstructured":"Foster DJ, Jones CK, Conn PJ. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discov Med. 2012;14(79):413\u201320.","journal-title":"Discov Med"},{"issue":"9","key":"1377_CR107","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","volume":"179","author":"SM Paul","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179(9):611\u201327. https:\/\/doi.org\/10.1176\/appi.ajp.21101083.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1377_CR108","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/archneurpsyc.1944.02290260061006","volume":"51","author":"LH Cohen","year":"1944","unstructured":"Cohen LH, Thale T, Tissenbaum MJ. Acetylcholine treatment of schizophrenia. Arch Neurol Psychiatry. 1944;51(2):171\u20135.","journal-title":"Arch Neurol Psychiatry"},{"issue":"1","key":"1377_CR109","doi-asserted-by":"publisher","first-page":"91","DOI":"10.31952\/amha.17.1.5","volume":"17","author":"G Armocida","year":"2019","unstructured":"Armocida G, Licata M, Gorini I, Ciliberti R. CTerapija acetilholinom u lije\u010denju shizofrenije\u2013iskustvo marija fiambertija u bolnici varese (1937). Acta Medico-historica Adriatica AMHA. 2019;17(1):91\u2013102.","journal-title":"Acta Medico-historica Adriatica AMHA"},{"issue":"5","key":"1377_CR110","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.npp.1301208","volume":"32","author":"S Barak","year":"2007","unstructured":"Barak S, Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology. 2007;32(5):989\u201399.","journal-title":"Neuropsychopharmacology"},{"key":"1377_CR111","unstructured":"Tom NR, Varghese GH, Alexander H, Kumar TRA, Sivakumar T. A case report on atropine induced psychosis (2015)."},{"key":"1377_CR112","first-page":"325","volume":"12","author":"SA Basha","year":"2017","unstructured":"Basha SA, Sathiswara B. Atropine induced psychosis: a report of two cases. Int Health Sci Res. 2017;12:325\u20137.","journal-title":"Int Health Sci Res"},{"issue":"3","key":"1377_CR113","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/13543784.2013.762355","volume":"22","author":"C-U Pae","year":"2013","unstructured":"Pae C-U. Role of the cholinesterase inhibitors in the treatment of schizophrenia. Expert Opin Investig Drugs. 2013;22(3):293\u20138.","journal-title":"Expert Opin Investig Drugs"},{"key":"1377_CR114","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/11530260-000000000-00000","volume":"24","author":"SR Ribeiz","year":"2010","unstructured":"Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs. 2010;24:303\u201317.","journal-title":"CNS Drugs"},{"key":"1377_CR115","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00002093-199703000-00004","volume":"11","author":"N Bodick","year":"1997","unstructured":"Bodick N, Offen W, Shannon H, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 1997;11:S16\u201322.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"1377_CR116","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0920-9964(99)00138-3","volume":"42","author":"HE Shannon","year":"2000","unstructured":"Shannon HE, Rasmussen K, Bymaster FP, et al. Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42(3):249\u201359. https:\/\/doi.org\/10.1016\/s0920-9964(99)00138-3.","journal-title":"Schizophr Res"},{"issue":"8","key":"1377_CR117","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2008.06091591.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1377_CR118","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","volume":"12","author":"AE Veroff","year":"1998","unstructured":"Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord. 1998;12(4):304\u201312.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"1377_CR119","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","volume":"40","author":"FP Bymaster","year":"1997","unstructured":"Bymaster FP, Whitesitt CA, Shannon HE, et al. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer\u2019s disease. Drug Dev Res. 1997;40(2):158\u201370.","journal-title":"Drug Dev Res"},{"key":"1377_CR120","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2165\/00002512-199711060-00004","volume":"11","author":"EE Avery","year":"1997","unstructured":"Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer\u2019s disease. Drugs Aging. 1997;11:450\u20139.","journal-title":"Drugs Aging"},{"issue":"8","key":"1377_CR121","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/j.1552-4604.1995.tb04123.x","volume":"35","author":"JJ Sramek","year":"1995","unstructured":"Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer\u2019s disease. J Clin Pharmacol. 1995;35(8):800\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1377_CR122","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.mp.4001924","volume":"12","author":"T Raedler","year":"2007","unstructured":"Raedler T, Bymaster F, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry. 2007;12(3):232\u201346.","journal-title":"Mol Psychiatry"},{"key":"1377_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113201","volume":"405","author":"DJ Foster","year":"2021","unstructured":"Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405: 113201.","journal-title":"Behav Brain Res"},{"issue":"5","key":"1377_CR124","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","volume":"148","author":"P Abrams","year":"2006","unstructured":"Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565\u201378.","journal-title":"Br J Pharmacol"},{"issue":"26","key":"1377_CR125","doi-asserted-by":"publisher","first-page":"8124","DOI":"10.1073\/pnas.1508846112","volume":"112","author":"JH Shin","year":"2015","unstructured":"Shin JH, Adrover MF, Wess J, Alvarez VA. Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. Proc Natl Acad Sci. 2015;112(26):8124\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"1377_CR126","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/jnp.3.4.383","volume":"3","author":"RS El-Mallakh","year":"1991","unstructured":"El-Mallakh RS, Kirch DG, Shelton R, et al. The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatry Clin Neurosci. 1991;3(4):383\u20136.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1377_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215290","author":"LJ Santiago","year":"2019","unstructured":"Santiago LJ, Abrol R. Understanding G protein selectivity of muscarinic acetylcholine receptors using computational methods. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20215290.","journal-title":"Int J Mol Sci"},{"key":"1377_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.606656","volume":"11","author":"ET van der Westhuizen","year":"2020","unstructured":"van der Westhuizen ET, Choy KHC, Valant C, et al. Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias. Front Pharmacol. 2020;11: 606656. https:\/\/doi.org\/10.3389\/fphar.2020.606656.","journal-title":"Front Pharmacol"},{"key":"1377_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105641","volume":"169","author":"A Rand\u00e1kov\u00e1","year":"2021","unstructured":"Rand\u00e1kov\u00e1 A, Jakub\u00edk J. Functionally selective and biased agonists of muscarinic receptors. Pharmacol Res. 2021;169: 105641. https:\/\/doi.org\/10.1016\/j.phrs.2021.105641.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1377_CR130","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41589-019-0453-9","volume":"16","author":"SJ Bradley","year":"2020","unstructured":"Bradley SJ, Molloy C, Valuskova P, et al. Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nat Chem Biol. 2020;16(3):240\u20139. https:\/\/doi.org\/10.1038\/s41589-019-0453-9.","journal-title":"Nat Chem Biol"},{"issue":"22","key":"1377_CR131","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1161\/circulationaha.117.028194","volume":"137","author":"JW Wisler","year":"2018","unstructured":"Wisler JW, Rockman HA, Lefkowitz RJ. Biased G protein-coupled receptor signaling: changing the paradigm of drug discovery. Circulation. 2018;137(22):2315\u20137. https:\/\/doi.org\/10.1161\/circulationaha.117.028194.","journal-title":"Circulation"},{"issue":"10","key":"1377_CR132","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","volume":"7","author":"B Dean","year":"2002","unstructured":"Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002;7(10):1083\u201391.","journal-title":"Mol Psychiatry"},{"issue":"7","key":"1377_CR133","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.mp.4001270","volume":"8","author":"E Tzavara","year":"2003","unstructured":"Tzavara E, Bymaster F, Felder C, et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2\/M4 muscarinic receptor knockout mice. Mol Psychiatry. 2003;8(7):673\u20139.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1377_CR134","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0014-2999(99)00607-X","volume":"383","author":"K Kitaichi","year":"1999","unstructured":"Kitaichi K, Day JC, Quirion R. A novel muscarinic M4 receptor antagonist provides further evidence of an autoreceptor role for the muscarinic M2 receptor sub-type. Eur J Pharmacol. 1999;383(1):53\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"1377_CR135","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","volume":"18","author":"ET Tzavara","year":"2004","unstructured":"Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies. FASEB J. 2004;18(12):1410\u20132.","journal-title":"FASEB J"},{"issue":"10422","key":"1377_CR136","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/s0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(23)02190-6.","journal-title":"Lancet"},{"key":"1377_CR137","unstructured":"https:\/\/karunatx.com\/pipeline-programs\/karxt\/."},{"key":"1377_CR138","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/B978-012351830-9\/50034-2","volume-title":"Functional neurobiology of aging","author":"ND Tsopelas","year":"2001","unstructured":"Tsopelas ND, Marin DB. 32\u2014Cholinergic treatments of Alzheimer\u2019s disease. In: Hof PR, Mobbs CV, editors. Functional neurobiology of aging. London: Academic Press; 2001. p. 475\u201386."},{"issue":"16","key":"1377_CR139","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1523\/jneurosci.0370-11.2011","volume":"31","author":"D Dencker","year":"2011","unstructured":"Dencker D, W\u00f6rtwein G, Weikop P, et al. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline. J Neurosci. 2011;31(16):5905\u20138. https:\/\/doi.org\/10.1523\/jneurosci.0370-11.2011.","journal-title":"J Neurosci"},{"issue":"8","key":"1377_CR140","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2017015.","journal-title":"N Engl J Med"},{"issue":"10\u201312","key":"1377_CR141","first-page":"43","volume":"19","author":"A Singh","year":"2022","unstructured":"Singh A. Xanomeline and trospium: a potential fixed drug combination (FDC) for schizophrenia\u2014a brief review of current data. Innov Clin Neurosci. 2022;19(10\u201312):43\u20137.","journal-title":"Innov Clin Neurosci"},{"key":"1377_CR142","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/B978-0-12-800634-4.00079-2","volume-title":"Neuropathology of drug addictions and substance misuse","author":"M Coppola","year":"2016","unstructured":"Coppola M, Mondola R, Oliva F, Luigi PR. Chapter 79\u2014Areca alkaloids and schizophrenia. In: Preedy VR, editor. Neuropathology of drug addictions and substance misuse. London: Academic Press; 2016. p. 794\u2013802."},{"issue":"5","key":"1377_CR143","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.3892\/mmr.2017.7502","volume":"16","author":"Z Li","year":"2017","unstructured":"Li Z, Jia K, Duan Y, Wang D, Zhou Z, Dong S. Xanomeline derivative EUK1001 attenuates Alzheimer\u2019s disease pathology in a triple transgenic mouse model. Mol Med Rep. 2017;16(5):7835\u201340. https:\/\/doi.org\/10.3892\/mmr.2017.7502.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1377_CR144","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465\u201373. https:\/\/doi.org\/10.1001\/archneur.1997.00550160091022.","journal-title":"Arch Neurol"},{"issue":"4","key":"1377_CR145","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","volume":"12","author":"AE Veroff","year":"1998","unstructured":"Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord. 1998;12(4):304\u201312. https:\/\/doi.org\/10.1097\/00002093-199812000-00010.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"1377_CR146","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","volume":"17","author":"FP Bymaster","year":"2003","unstructured":"Bymaster FP, Carter PA, Yamada M, et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci. 2003;17(7):1403\u201310. https:\/\/doi.org\/10.1046\/j.1460-9568.2003.02588.x.","journal-title":"Eur J Neurosci"},{"issue":"6","key":"1377_CR147","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/sj.npp.1300151","volume":"28","author":"MB Andersen","year":"2003","unstructured":"Andersen MB, Fink-Jensen A, Peacock L, et al. The muscarinic M1\/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in cebus apella monkeys. Neuropsychopharmacology. 2003;28(6):1168\u201375. https:\/\/doi.org\/10.1038\/sj.npp.1300151.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1377_CR148","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9(2):159\u201386. https:\/\/doi.org\/10.1111\/j.1527-3458.2003.tb00247.x.","journal-title":"CNS Drug Rev"},{"issue":"1","key":"1377_CR149","first-page":"271","volume":"269","author":"HE Shannon","year":"1994","unstructured":"Shannon HE, Bymaster FP, Calligaro DO, et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther. 1994;269(1):271\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1377_CR150","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1124\/mol.106.023762","volume":"70","author":"J Jakub\u00edk","year":"2006","unstructured":"Jakub\u00edk J, El-Fakahany EE, Dolezal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Mol Pharmacol. 2006;70(2):656\u201366. https:\/\/doi.org\/10.1124\/mol.106.023762.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1377_CR151","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/acschemneuro.8b00625","volume":"10","author":"CA Thorn","year":"2019","unstructured":"Thorn CA, Moon J, Bourbonais CA, et al. Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci. 2019;10(3):1753\u201364. https:\/\/doi.org\/10.1021\/acschemneuro.8b00625.","journal-title":"ACS Chem Neurosci"},{"issue":"1\u20133","key":"1377_CR152","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","volume":"605","author":"JN Heinrich","year":"2009","unstructured":"Heinrich JN, Butera JA, Carrick T, et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009;605(1\u20133):53\u20136. https:\/\/doi.org\/10.1016\/j.ejphar.2008.12.044.","journal-title":"Eur J Pharmacol"},{"issue":"15","key":"1377_CR153","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1523\/jneurosci.22-15-06347.2002","volume":"22","author":"W Zhang","year":"2002","unstructured":"Zhang W, Yamada M, Gomeza J, Basile AS, Wess J. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1\u2013M5 muscarinic receptor knock-out mice. J Neurosci. 2002;22(15):6347\u201352. https:\/\/doi.org\/10.1523\/jneurosci.22-15-06347.2002.","journal-title":"J Neurosci"},{"issue":"10","key":"1377_CR154","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1021\/cn500128b","volume":"5","author":"M Bubser","year":"2014","unstructured":"Bubser M, Bridges TM, Dencker D, et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci. 2014;5(10):920\u201342. https:\/\/doi.org\/10.1021\/cn500128b.","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"1377_CR155","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrd2379","volume":"6","author":"J Wess","year":"2007","unstructured":"Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007;6(9):721\u201333. https:\/\/doi.org\/10.1038\/nrd2379.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1377_CR156","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","volume":"18","author":"ET Tzavara","year":"2004","unstructured":"Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 2004;18(12):1410\u20132. https:\/\/doi.org\/10.1096\/fj.04-1575fje.","journal-title":"FASEB J"},{"issue":"7","key":"1377_CR157","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","volume":"125","author":"J Watson","year":"1998","unstructured":"Watson J, Brough S, Coldwell MC, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1998;125(7):1413\u201320. https:\/\/doi.org\/10.1038\/sj.bjp.0702201.","journal-title":"Br J Pharmacol"},{"key":"1377_CR158","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14316","author":"PJ Weiden","year":"2022","unstructured":"Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic efficacy of KarXT (xanomeline-trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022. https:\/\/doi.org\/10.4088\/JCP.21m14316.","journal-title":"J Clin Psychiatry"},{"key":"1377_CR159","first-page":"S174","volume-title":"KarXT, a combination of the M1\/M4 cholinergic receptor agonist xanomeline and trospium for the treatment of psychosis and cognitive impairment in schizophrenia: phase I studies","author":"S Brannan","year":"2018","unstructured":"Brannan S, Miller A, Paul S, Breier A. KarXT, a combination of the M1\/M4 cholinergic receptor agonist xanomeline and trospium for the treatment of psychosis and cognitive impairment in schizophrenia: phase I studies. London: Nature Publishing Group; 2018. p. S174\u20135."},{"key":"1377_CR160","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","volume":"240","author":"A Breier","year":"2023","unstructured":"Breier A, Brannan SK, Paul SM, Miller AC. Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology. 2023;240:1191\u20138.","journal-title":"Psychopharmacology"},{"key":"1377_CR161","unstructured":"NCT02831231. https:\/\/clinicaltrials.gov\/study\/NCT02831231."},{"key":"1377_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.606656","author":"ET van der Westhuizen","year":"2021","unstructured":"van der Westhuizen ET, Choy KHC, Valant C, et al. Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2020.606656.","journal-title":"Front Pharmacol"},{"key":"1377_CR163","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fpsyt.2014.00047","volume":"5","author":"R Brisch","year":"2014","unstructured":"Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47. https:\/\/doi.org\/10.3389\/fpsyt.2014.00047.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1377_CR164","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0166-2236(96)10064-3","volume":"20","author":"AA Grace","year":"1997","unstructured":"Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997;20(1):31\u20137. https:\/\/doi.org\/10.1016\/s0166-2236(96)10064-3.","journal-title":"Trends Neurosci"},{"issue":"8","key":"1377_CR165","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1523\/jneurosci.03-08-01607.1983","volume":"3","author":"LA Chiodo","year":"1983","unstructured":"Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3(8):1607\u201319. https:\/\/doi.org\/10.1523\/jneurosci.03-08-01607.1983.","journal-title":"J Neurosci"},{"issue":"34","key":"1377_CR166","doi-asserted-by":"publisher","first-page":"12330","DOI":"10.1523\/jneurosci.2808-11.2011","volume":"31","author":"O Valenti","year":"2011","unstructured":"Valenti O, Cifelli P, Gill KM, Grace AA. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci. 2011;31(34):12330\u20138. https:\/\/doi.org\/10.1523\/jneurosci.2808-11.2011.","journal-title":"J Neurosci"},{"issue":"1","key":"1377_CR167","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.physbeh.2011.04.052","volume":"104","author":"GP Mark","year":"2011","unstructured":"Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. Physiol Behav. 2011;104(1):76\u201381. https:\/\/doi.org\/10.1016\/j.physbeh.2011.04.052.","journal-title":"Physiol Behav"},{"key":"1377_CR168","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","volume":"282","author":"CP Ford","year":"2014","unstructured":"Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13\u201322. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.01.025.","journal-title":"Neuroscience"},{"issue":"10","key":"1377_CR169","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1523\/jneurosci.11-10-03218.1991","volume":"11","author":"AI Levey","year":"1991","unstructured":"Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991;11(10):3218\u201326. https:\/\/doi.org\/10.1523\/jneurosci.11-10-03218.1991.","journal-title":"J Neurosci"},{"issue":"18","key":"1377_CR170","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.1073\/pnas.96.18.10483","volume":"96","author":"J Gomeza","year":"1999","unstructured":"Gomeza J, Zhang L, Kostenis E, et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA. 1999;96(18):10483\u20138. https:\/\/doi.org\/10.1073\/pnas.96.18.10483.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1377_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-5-10","author":"H Koshimizu","year":"2012","unstructured":"Koshimizu H, Leiter LM, Miyakawa T. M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition. Mol Brain. 2012. https:\/\/doi.org\/10.1186\/1756-6606-5-10.","journal-title":"Mol Brain"},{"issue":"6","key":"1377_CR172","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.neuron.2017.12.008","volume":"96","author":"MS Moehle","year":"2017","unstructured":"Moehle MS, Pancani T, Byun N, et al. Cholinergic projections to the substantia nigra pars reticulata inhibit dopamine modulation of basal ganglia through the M(4) muscarinic receptor. Neuron. 2017;96(6):1358-1372.e4. https:\/\/doi.org\/10.1016\/j.neuron.2017.12.008.","journal-title":"Neuron"},{"issue":"2","key":"1377_CR173","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.brainresrev.2008.02.003","volume":"58","author":"J Mena-Segovia","year":"2008","unstructured":"Mena-Segovia J, Winn P, Bolam JP. Cholinergic modulation of midbrain dopaminergic systems. Brain Res Rev. 2008;58(2):265\u201371. https:\/\/doi.org\/10.1016\/j.brainresrev.2008.02.003.","journal-title":"Brain Res Rev"},{"issue":"2","key":"1377_CR174","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neuron.2016.03.028","volume":"90","author":"C Xiao","year":"2016","unstructured":"Xiao C, Cho JR, Zhou C, et al. Cholinergic mesopontine signals govern locomotion and reward through dissociable midbrain pathways. Neuron. 2016;90(2):333\u201347. https:\/\/doi.org\/10.1016\/j.neuron.2016.03.028.","journal-title":"Neuron"},{"issue":"1\u20133","key":"1377_CR175","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.schres.2013.01.023","volume":"146","author":"E Scarr","year":"2013","unstructured":"Scarr E, Um JY, Cowie TF, Dean B. Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophr Res. 2013;146(1\u20133):279\u201384. https:\/\/doi.org\/10.1016\/j.schres.2013.01.023.","journal-title":"Schizophr Res"},{"issue":"10","key":"1377_CR176","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.biopsych.2006.08.050","volume":"61","author":"E Scarr","year":"2007","unstructured":"Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry. 2007;61(10):1161\u201370.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"1377_CR177","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/s41380-018-0206-2","volume":"25","author":"SE Yohn","year":"2020","unstructured":"Yohn SE, Foster DJ, Covey DP, et al. Activation of the mGlu(1) metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M(4) muscarinic receptor allosteric modulators. Mol Psychiatry. 2020;25(11):2786\u201399. https:\/\/doi.org\/10.1038\/s41380-018-0206-2.","journal-title":"Mol Psychiatry"},{"issue":"10","key":"1377_CR178","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1021\/cb500560h","volume":"9","author":"HP Cho","year":"2014","unstructured":"Cho HP, Garcia-Barrantes PM, Brogan JT, et al. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. ACS Chem Biol. 2014;9(10):2334\u201346. https:\/\/doi.org\/10.1021\/cb500560h.","journal-title":"ACS Chem Biol"},{"issue":"3","key":"1377_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032849","volume":"7","author":"MA Ayoub","year":"2012","unstructured":"Ayoub MA, Angelicheva D, Vile D, et al. Deleterious GRM1 mutations in schizophrenia. PLoS\u00a0One. 2012;7(3): e32849. https:\/\/doi.org\/10.1371\/journal.pone.0032849.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"1377_CR180","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1021\/cn500003z","volume":"5","author":"T Pancani","year":"2014","unstructured":"Pancani T, Bolarinwa C, Smith Y, Lindsley CW, Conn PJ, Xiang Z. M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. ACS Chem Neurosci. 2014;5(4):318\u201324. https:\/\/doi.org\/10.1021\/cn500003z.","journal-title":"ACS Chem Neurosci"},{"key":"1377_CR181","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fnmol.2019.00185","volume":"12","author":"G Lee","year":"2019","unstructured":"Lee G, Zhou Y. NMDAR Hypofunction animal models of schizophrenia. Front Mol Neurosci. 2019;12:185. https:\/\/doi.org\/10.3389\/fnmol.2019.00185.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"1377_CR182","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1176\/appi.ajp.2020.20101481","volume":"177","author":"JT Coyle","year":"2020","unstructured":"Coyle JT, Ruzicka WB, Balu DT. Fifty years of research on schizophrenia: the ascendance of the glutamatergic synapse. Am J Psychiatry. 2020;177(12):1119\u201328. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20101481.","journal-title":"Am J Psychiatry"},{"key":"1377_CR183","volume-title":"Evaluating novel muscarinic acetylcholine receptor potentiators for the treatment of cognitive deficits in schizophrenia","author":"MD Grannan","year":"2016","unstructured":"Grannan MD. Evaluating novel muscarinic acetylcholine receptor potentiators for the treatment of cognitive deficits in schizophrenia. Nashville: Vanderbilt University; 2016."},{"issue":"10","key":"1377_CR184","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","volume":"7","author":"B Dean","year":"2002","unstructured":"Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002;7(10):1083\u201391. https:\/\/doi.org\/10.1038\/sj.mp.4001199.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1377_CR185","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ajmg.b.20020","volume":"119","author":"D Mancama","year":"2003","unstructured":"Mancama D, Arranz M, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2003;119(1):2\u20136.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"2","key":"1377_CR186","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.mp.4000684","volume":"5","author":"B Dean","year":"2000","unstructured":"Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL. Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia. Mol Psychiatry. 2000;5(2):203\u20137. https:\/\/doi.org\/10.1038\/sj.mp.4000684.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1377_CR187","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0920-9964(94)90071-x","volume":"12","author":"V Haroutunian","year":"1994","unstructured":"Haroutunian V, Davidson M, Kanof PD, et al. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994;12(2):137\u201344. https:\/\/doi.org\/10.1016\/0920-9964(94)90071-x.","journal-title":"Schizophr Res"},{"issue":"1","key":"1377_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568007023339544","volume":"1","author":"MJ Marino","year":"2002","unstructured":"Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl d-aspartate receptor. Curr Drug Targets CNS Neurol Disord. 2002;1(1):1\u201316. https:\/\/doi.org\/10.2174\/1568007023339544.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"19","key":"1377_CR189","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.1073\/pnas.95.19.11465","volume":"95","author":"MJ Marino","year":"1998","unstructured":"Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA. 1998;95(19):11465\u201370. https:\/\/doi.org\/10.1073\/pnas.95.19.11465.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1377_CR190","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nn992","volume":"6","author":"SG Anagnostaras","year":"2003","unstructured":"Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6(1):51\u20138. https:\/\/doi.org\/10.1038\/nn992.","journal-title":"Nat Neurosci"},{"issue":"12","key":"1377_CR191","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1523\/jneurosci.6393-09.2010","volume":"30","author":"AA Davis","year":"2010","unstructured":"Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci. 2010;30(12):4190\u20136. https:\/\/doi.org\/10.1523\/jneurosci.6393-09.2010.","journal-title":"J Neurosci"},{"issue":"2","key":"1377_CR192","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajpath.2011.04.041","volume":"179","author":"R Medeiros","year":"2011","unstructured":"Medeiros R, Kitazawa M, Caccamo A, et al. Loss of muscarinic M1 receptor exacerbates alzheimer\u2019s disease\u2013like pathology and cognitive decline. Am J Pathol. 2011;179(2):980\u201391.","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"1377_CR193","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1471-4159.2011.07507.x","volume":"120","author":"A Fisher","year":"2012","unstructured":"Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer\u2019s disease. J Neurochem. 2012;120(Suppl 1):22\u201333. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07507.x.","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"1377_CR194","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/s0006-8993(01)02484-2","volume":"905","author":"TG Beach","year":"2001","unstructured":"Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res. 2001;905(1\u20132):220\u20133. https:\/\/doi.org\/10.1016\/s0006-8993(01)02484-2.","journal-title":"Brain Res"},{"issue":"5","key":"1377_CR195","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","volume":"49","author":"A Caccamo","year":"2006","unstructured":"Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671\u201382. https:\/\/doi.org\/10.1016\/j.neuron.2006.01.020.","journal-title":"Neuron"},{"issue":"2","key":"1377_CR196","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1006\/exnr.2000.7397","volume":"163","author":"RT Bartus","year":"2000","unstructured":"Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163(2):495\u2013529.","journal-title":"Exp Neurol"},{"issue":"4","key":"1377_CR197","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","volume":"36","author":"P Anand","year":"2013","unstructured":"Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer\u2019s disease. Arch Pharm Res. 2013;36(4):375\u201399. https:\/\/doi.org\/10.1007\/s12272-013-0036-3.","journal-title":"Arch Pharm Res"},{"key":"1377_CR198","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.niox.2023.03.003","volume":"134\u2013135","author":"A Azargoonjahromi","year":"2023","unstructured":"Azargoonjahromi A. Dual role of nitric oxide in Alzheimer\u2019s disease. Nitric Oxide. 2023;134\u2013135:23\u201337. https:\/\/doi.org\/10.1016\/j.niox.2023.03.003.","journal-title":"Nitric Oxide"},{"key":"1377_CR199","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimer\u2019s Dementia Transl Res Clin Interv. 2019;5:272\u201393.","journal-title":"Alzheimer's Dementia Transl Res Clin Interv"},{"key":"1377_CR200","volume":"12","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Central Nerv Syst Dis. 2020;12: 1179573520907397.","journal-title":"J Central Nerv Syst Dis"},{"issue":"1","key":"1377_CR201","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"KG Yiannopoulou","year":"2013","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disord. 2013;6(1):19\u201333.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"1377_CR202","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","volume":"5","author":"A Fisher","year":"2008","unstructured":"Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer\u2019s disease. Neurotherapeutics. 2008;5(3):433\u201342. https:\/\/doi.org\/10.1016\/j.nurt.2008.05.002.","journal-title":"Neurotherapeutics"},{"key":"1377_CR203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2125.2004.01848.x","volume":"58","author":"S Jackson","year":"2004","unstructured":"Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer\u2019s disease. Br J Clin Pharmacol. 2004;58:1\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1377_CR204","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/tcrm.S323387","volume":"17","author":"S Ruangritchankul","year":"2021","unstructured":"Ruangritchankul S, Chantharit P, Srisuma S, Gray LC. Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Ther Clin Risk Manag. 2021;17:927\u201349. https:\/\/doi.org\/10.2147\/tcrm.S323387.","journal-title":"Ther Clin Risk Manag"},{"issue":"16","key":"1377_CR205","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1113\/jphysiol.2014.275453","volume":"592","author":"F Yi","year":"2014","unstructured":"Yi F, Ball J, Stoll KE, et al. Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition. J Physiol. 2014;592(16):3463\u201394. https:\/\/doi.org\/10.1113\/jphysiol.2014.275453.","journal-title":"J Physiol"},{"issue":"9","key":"1377_CR206","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acschemneuro.7b00398","volume":"9","author":"D Neuhofer","year":"2018","unstructured":"Neuhofer D, Lassalle O, Manzoni OJ. Muscarinic M1 receptor modulation of synaptic plasticity in nucleus accumbens of wild-type and fragile X mice. ACS Chem Neurosci. 2018;9(9):2233\u201340. https:\/\/doi.org\/10.1021\/acschemneuro.7b00398.","journal-title":"ACS Chem Neurosci"},{"key":"1377_CR207","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuropharm.2017.03.017","volume":"118","author":"X Lv","year":"2017","unstructured":"Lv X, Dickerson JW, Rook JM, Lindsley CW, Conn PJ, Xiang Z. M(1) muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. Neuropharmacology. 2017;118:209\u201322. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.017.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1377_CR208","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.neuron.2019.05.031","volume":"103","author":"TC Francis","year":"2019","unstructured":"Francis TC, Yano H, Demarest TG, Shen H, Bonci A. High-frequency activation of nucleus accumbens D1-MSNs drives excitatory potentiation on D2-MSNs. Neuron. 2019;103(3):432-444.e3. https:\/\/doi.org\/10.1016\/j.neuron.2019.05.031.","journal-title":"Neuron"},{"issue":"26","key":"1377_CR209","doi-asserted-by":"publisher","first-page":"15312","DOI":"10.1073\/pnas.261583798","volume":"98","author":"DJ Gerber","year":"2001","unstructured":"Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA. 2001;98(26):15312\u20137. https:\/\/doi.org\/10.1073\/pnas.261583798.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"1377_CR210","doi-asserted-by":"publisher","first-page":"10422","DOI":"10.1523\/jneurosci.1850-08.2008","volume":"28","author":"CK Jones","year":"2008","unstructured":"Jones CK, Brady AE, Davis AA, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci. 2008;28(41):10422\u201333. https:\/\/doi.org\/10.1523\/jneurosci.1850-08.2008.","journal-title":"J Neurosci"},{"issue":"2","key":"1377_CR211","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.bmcl.2015.11.053","volume":"26","author":"JE Davoren","year":"2016","unstructured":"Davoren JE, O\u2019Neil SV, Anderson DP, et al. Design and optimization of selective azaindole amide M1 positive allosteric modulators. Bioorg Med Chem Lett. 2016;26(2):650\u20135. https:\/\/doi.org\/10.1016\/j.bmcl.2015.11.053.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"1377_CR212","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/npp.2015.189","volume":"41","author":"A Ghoshal","year":"2016","unstructured":"Ghoshal A, Rook JM, Dickerson JW, et al. Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology. 2016;41(2):598\u2013610. https:\/\/doi.org\/10.1038\/npp.2015.189.","journal-title":"Neuropsychopharmacology"},{"key":"1377_CR213","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/bs.apha.2019.12.003","volume":"88","author":"M Scarpa","year":"2020","unstructured":"Scarpa M, Hesse S, Bradley SJ. M1 muscarinic acetylcholine receptors: a therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer\u2019s disease? Adv Pharmacol. 2020;88:277\u2013310. https:\/\/doi.org\/10.1016\/bs.apha.2019.12.003.","journal-title":"Adv Pharmacol"},{"issue":"Pt C","key":"1377_CR214","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neuropharm.2018.01.028","volume":"136","author":"CC Felder","year":"2018","unstructured":"Felder CC, Goldsmith PJ, Jackson K, et al. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Neuropharmacology. 2018;136(Pt C):449\u201358. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.028.","journal-title":"Neuropharmacology"},{"issue":"7","key":"1377_CR215","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/hipo.22732","volume":"27","author":"CA Thorn","year":"2017","unstructured":"Thorn CA, Popiolek M, Stark E, Edgerton JR. Effects of M1 and M4 activation on excitatory synaptic transmission in CA1. Hippocampus. 2017;27(7):794\u2013810. https:\/\/doi.org\/10.1002\/hipo.22732.","journal-title":"Hippocampus"},{"issue":"2","key":"1377_CR216","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1152\/jn.00686.2010","volume":"105","author":"S Dasari","year":"2011","unstructured":"Dasari S, Gulledge AT. M1 and M4 receptors modulate hippocampal pyramidal neurons. J Neurophysiol. 2011;105(2):779\u201392. https:\/\/doi.org\/10.1152\/jn.00686.2010.","journal-title":"J Neurophysiol"},{"issue":"13","key":"1377_CR217","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/s41386-020-00812-7","volume":"45","author":"RW Gould","year":"2020","unstructured":"Gould RW, Russell JK, Nedelcovych MT, et al. Modulation of arousal and sleep\/wake architecture by M(1) PAM VU0453595 across young and aged rodents and nonhuman primates. Neuropsychopharmacology. 2020;45(13):2219\u201328. https:\/\/doi.org\/10.1038\/s41386-020-00812-7.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1377_CR218","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1124\/jpet.116.235788","volume":"359","author":"KH Choy","year":"2016","unstructured":"Choy KH, Shackleford DM, Malone DT, et al. Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior. J Pharmacol Exp Ther. 2016;359(2):354\u201365. https:\/\/doi.org\/10.1124\/jpet.116.235788.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1377_CR219","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neuron.2020.02.030","volume":"106","author":"VC Galvin","year":"2020","unstructured":"Galvin VC, Yang ST, Paspalas CD, et al. Muscarinic M1 receptors modulate working memory performance and activity via KCNQ potassium channels in the primate prefrontal cortex. Neuron. 2020;106(4):649-661.e4. https:\/\/doi.org\/10.1016\/j.neuron.2020.02.030.","journal-title":"Neuron"},{"issue":"45","key":"1377_CR220","doi-asserted-by":"publisher","first-page":"14271","DOI":"10.1523\/jneurosci.3930-09.2009","volume":"29","author":"JK Shirey","year":"2009","unstructured":"Shirey JK, Brady AE, Jones PJ, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009;29(45):14271\u201386. https:\/\/doi.org\/10.1523\/jneurosci.3930-09.2009.","journal-title":"J Neurosci"},{"issue":"3","key":"1377_CR221","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuropharm.2005.03.019","volume":"49","author":"AA Grishin","year":"2005","unstructured":"Grishin AA, Benquet P, Gerber U. Muscarinic receptor stimulation reduces NMDA responses in CA3 hippocampal pyramidal cells via Ca2+-dependent activation of tyrosine phosphatase. Neuropharmacology. 2005;49(3):328\u201337. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.03.019.","journal-title":"Neuropharmacology"},{"issue":"10","key":"1377_CR222","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","volume":"6","author":"RW Gould","year":"2015","unstructured":"Gould RW, Dencker D, Grannan M, et al. Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice. ACS Chem Neurosci. 2015;6(10):1683\u201395. https:\/\/doi.org\/10.1021\/acschemneuro.5b00123.","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"1377_CR223","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.neuron.2010.11.018","volume":"68","author":"KA Buchanan","year":"2010","unstructured":"Buchanan KA, Petrovic MM, Chamberlain SE, Marrion NV, Mellor JR. Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels. Neuron. 2010;68(5):948\u201363. https:\/\/doi.org\/10.1016\/j.neuron.2010.11.018.","journal-title":"Neuron"},{"issue":"12","key":"1377_CR224","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1021\/acschemneuro.6b00230","volume":"7","author":"MD Grannan","year":"2016","unstructured":"Grannan MD, Mielnik CA, Moran SP, et al. Prefrontal cortex-mediated impairments in a genetic model of nmda receptor hypofunction are reversed by the novel M(1) PAM VU6004256. ACS Chem Neurosci. 2016;7(12):1706\u201316. https:\/\/doi.org\/10.1021\/acschemneuro.6b00230.","journal-title":"ACS Chem Neurosci"},{"issue":"1\u20132","key":"1377_CR225","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jneuroim.2014.02.008","volume":"269","author":"AL Jones","year":"2014","unstructured":"Jones AL, Mowry BJ, McLean DE, Mantzioris BX, Pender MP, Greer JM. Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. J Neuroimmunol. 2014;269(1\u20132):68\u201375. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.02.008.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"1377_CR226","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0165-5728(03)00252-2","volume":"141","author":"S Tanaka","year":"2003","unstructured":"Tanaka S, Matsunaga H, Kimura M, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003;141(1\u20132):155\u201364. https:\/\/doi.org\/10.1016\/s0165-5728(03)00252-2.","journal-title":"J Neuroimmunol"},{"issue":"1\u20133","key":"1377_CR227","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","volume":"603","author":"ML Woolley","year":"2009","unstructured":"Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharmacol. 2009;603(1\u20133):147\u20139. https:\/\/doi.org\/10.1016\/j.ejphar.2008.12.020.","journal-title":"Eur J Pharmacol"},{"key":"1377_CR228","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-23274-9_13","volume":"208","author":"RD Harvey","year":"2012","unstructured":"Harvey RD. Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol. 2012;208:299\u2013316. https:\/\/doi.org\/10.1007\/978-3-642-23274-9_13.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"1377_CR229","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1134\/S1068162023010211","volume":"49","author":"AV Osipov","year":"2023","unstructured":"Osipov AV, Averin AS, Shaykhutdinova ER, Dyachenko IA, Tsetlin VI, Utkin YN. Muscarinic and nicotinic acetylcholine receptors in the regulation of the cardiovascular system. Russ J Bioorg Chem. 2023;49(1):1\u201318. https:\/\/doi.org\/10.1134\/S1068162023010211.","journal-title":"Russ J Bioorg Chem"},{"issue":"1","key":"1377_CR230","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41398-023-02400-x","volume":"13","author":"SE Jones","year":"2023","unstructured":"Jones SE, Harvey PD. Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system. Transl Psychiatry. 2023;13(1):100. https:\/\/doi.org\/10.1038\/s41398-023-02400-x.","journal-title":"Transl Psychiatry"},{"key":"1377_CR231","doi-asserted-by":"crossref","unstructured":"Correll CU, Miller A, Sawchak S, Paul S, Brannan S. Safety and efficacy of KarXT (xanomeline-trospium) in patients with schizophrenia: results from a phase 3, randomized, double-blind, placebo-controlled trial (EMERGENT-2) (2022).","DOI":"10.1016\/j.nsa.2022.100288"},{"issue":"10422","key":"1377_CR232","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160\u201370.","journal-title":"Lancet"},{"issue":"1","key":"1377_CR233","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Angelov AS, Miller AC, Weiden PJ, Brannan SK. Safety and tolerability of KarXT (xanomeline\u2013trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia. 2022;8(1):109.","journal-title":"Schizophrenia"},{"issue":"8","key":"1377_CR234","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"1377_CR235","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","volume":"12","author":"C Sauder","year":"2022","unstructured":"Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry. 2022;12(1):491.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"1377_CR236","doi-asserted-by":"publisher","first-page":"40913","DOI":"10.4088\/JCP.21m14316","volume":"83","author":"PJ Weiden","year":"2022","unstructured":"Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic efficacy of KarXT (xanomeline\u2013trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022;83(3):40913.","journal-title":"J Clin Psychiatry"},{"key":"1377_CR237","unstructured":"NCT04659161. https:\/\/clinicaltrials.gov\/study\/NCT04659161."},{"key":"1377_CR238","unstructured":"NCT03697252. https:\/\/www.clinicaltrials.gov\/study\/NCT03697252?cond=NCT03697252&rank=1."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01377-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T20:04:48Z","timestamp":1721678688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01377-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":238,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01377-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"10 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review did not receive any specific grants from public, private, or not-for-profit funding organizations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"There are no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data and materials are within the paper.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"A.A. has accomplished all parts of this review article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}